Cargando…

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

The link between glucose and HbA1c at steady state has previously been described using steady-state or longitudinal relationships. We evaluated five published methods for prediction of HbA1c after 26/28 weeks using data from four clinical trials. Methods (1) and (2): steady-state regression of HbA1c...

Descripción completa

Detalles Bibliográficos
Autores principales: Møller, J B, Kristensen, N R, Klim, S, Karlsson, M O, Ingwersen, S H, Kjellsson, M C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120014/
https://www.ncbi.nlm.nih.gov/pubmed/24988185
http://dx.doi.org/10.1038/psp.2014.20
_version_ 1782329033204170752
author Møller, J B
Kristensen, N R
Klim, S
Karlsson, M O
Ingwersen, S H
Kjellsson, M C
author_facet Møller, J B
Kristensen, N R
Klim, S
Karlsson, M O
Ingwersen, S H
Kjellsson, M C
author_sort Møller, J B
collection PubMed
description The link between glucose and HbA1c at steady state has previously been described using steady-state or longitudinal relationships. We evaluated five published methods for prediction of HbA1c after 26/28 weeks using data from four clinical trials. Methods (1) and (2): steady-state regression of HbA1c on fasting plasma glucose and mean plasma glucose, respectively, (3) an indirect response model of fasting plasma glucose effects on HbA1c, (4) model of glycosylation of red blood cells, and (5) coupled indirect response model for mean plasma glucose and HbA1c. Absolute mean prediction errors were 0.61, 0.38, 0.55, 0.37, and 0.15% points, respectively, for Methods 1 through 5. This indicates that predictions improved by using mean plasma glucose instead of fasting plasma glucose, by inclusion of longitudinal glucose data and further by inclusion of longitudinal HbA1c data until 12 weeks. For prediction of trial outcome, the longitudinal models based on mean plasma glucose (Methods 4 and 5) had substantially better performance compared with the other methods.
format Online
Article
Text
id pubmed-4120014
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41200142014-08-15 Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches Møller, J B Kristensen, N R Klim, S Karlsson, M O Ingwersen, S H Kjellsson, M C CPT Pharmacometrics Syst Pharmacol Original Article The link between glucose and HbA1c at steady state has previously been described using steady-state or longitudinal relationships. We evaluated five published methods for prediction of HbA1c after 26/28 weeks using data from four clinical trials. Methods (1) and (2): steady-state regression of HbA1c on fasting plasma glucose and mean plasma glucose, respectively, (3) an indirect response model of fasting plasma glucose effects on HbA1c, (4) model of glycosylation of red blood cells, and (5) coupled indirect response model for mean plasma glucose and HbA1c. Absolute mean prediction errors were 0.61, 0.38, 0.55, 0.37, and 0.15% points, respectively, for Methods 1 through 5. This indicates that predictions improved by using mean plasma glucose instead of fasting plasma glucose, by inclusion of longitudinal glucose data and further by inclusion of longitudinal HbA1c data until 12 weeks. For prediction of trial outcome, the longitudinal models based on mean plasma glucose (Methods 4 and 5) had substantially better performance compared with the other methods. Nature Publishing Group 2014-07 2014-07-02 /pmc/articles/PMC4120014/ /pubmed/24988185 http://dx.doi.org/10.1038/psp.2014.20 Text en Copyright © 2014 American Society for Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Møller, J B
Kristensen, N R
Klim, S
Karlsson, M O
Ingwersen, S H
Kjellsson, M C
Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
title Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
title_full Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
title_fullStr Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
title_full_unstemmed Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
title_short Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
title_sort methods for predicting diabetes phase iii efficacy outcome from early data: superior performance obtained using longitudinal approaches
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120014/
https://www.ncbi.nlm.nih.gov/pubmed/24988185
http://dx.doi.org/10.1038/psp.2014.20
work_keys_str_mv AT møllerjb methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches
AT kristensennr methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches
AT klims methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches
AT karlssonmo methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches
AT ingwersensh methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches
AT kjellssonmc methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches